BioMarin Pharmaceutical Inc.
corporate_fare Company Profile
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for BMRN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-31, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for BMRN spans 8-K, 8-K/A, 10-Q, DEF 14A.
Recent high-impact activity:
- BioMarin Secures 20% U.S. Royalty on Ascendis' Yuviwel in Global Patent Settlement
- BioMarin Secures 20% Royalty on Ascendis' Yuviwel in Global Patent Settlement
- BioMarin to Acquire Alesta Therapeutics for $275M Upfront, Up to $215M in Milestones
- BioMarin Buys Alesta for ALE1, First Oral Hypophosphatasia Therapy
- BioMarin Lifts Full-Year Outlook as Q2 Revenue Climbs 20% to $990M on Robust VOXZOGO Demand
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for BMRN, detected from its recent SEC filings · based on capital-structure filings through 2026-04-21.
Annual Shareholder Meeting Scheduled · Significant Equity Incentive Plan Expansion Proposed
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →